Daniel Cavanaugh Pierce

US Patent:

47602546, Jul 26, 1988

Filed:

Jun 7, 1985

Appl. No.:

6/742233

Inventors:

Daniel T. Pierce - Gaithersburg MD
Robert J. Celotta - Gaithersburg MD
John Unguris - Damascus MD

International Classification:

G01N 2700
H01J 4000
H01J 4700

US Classification:

250305

Abstract:

Provided herein are a device and a method for determining the spin polarization of an electron beam where the device and method contemplate diffusely backscattering the beam from an electron opaque target, at a kinetic energy less than 10,000 electron volts, collecting the scattered electrons which may be of a preselected energy range and within a predetermined solid angle relative to the target and the collector, and measuring the number of scattered electrons which were collected.

US Patent:

39683761, Jul 6, 1976

Filed:

Jun 3, 1975

Appl. No.:

5/581837

Inventors:

Daniel Thornton Pierce - Gaithersburg MD
Felix Andrea Meier - Kilchberg, Zurich, CH
Hans-Christoph Siegmann - Greifensee, Zurich, CH

International Classification:

G21G 400
H01J 3900

US Classification:

250493

Abstract:

The invention concerns a method of producing intense beams of polarized free electrons in which a semiconductor with a spin orbit split valence band and negative electron affinity is used as a photocathode and irradiated with circularly polarized light.

US Patent:

20190361005, Nov 28, 2019

Filed:

May 22, 2019

Appl. No.:

16/420031

Inventors:

- Summit NJ, US
Joshua Hansen - La Jolla CA, US
Courtney G. Havens - San Diego CA, US
Gang Lu - San Diego CA, US
Daniel W. Pierce - Belmont CA, US
Lilly L. Wong - Solana Beach CA, US

International Classification:

G01N 33/50
G01N 33/68
G01N 33/574
A61K 31/496

Abstract:

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

US Patent:

20190030018, Jan 31, 2019

Filed:

Jun 29, 2018

Appl. No.:

16/024581

Inventors:

- Summit NJ, US
James Carmichael - Nottingham, GB
Soraya Carrancio - San Diego CA, US
Jinhong Fan - San Mateo CA, US
Rajan Gupta - Bridgewater NJ, US
Gang Lu - San Diego CA, US
Kyle MacBeth - San Francisco CA, US
Emily Pace - Orinda CA, US
Daniel Pierce - Belmont CA, US
Michael Pourdehnad - San Francisco CA, US
Yu Pu - East Hanover NJ, US
Peng Wang - Westfield NJ, US
Naijun Wu - Princeton NJ, US
Sheena Yao - San Francisco CA, US

International Classification:

A61K 31/454
A61K 47/40
A61K 9/00
A61K 45/06
A61K 31/436
A61K 9/19
A61P 35/02

Abstract:

Provided herein are formulations and methods of use of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.